FDA approves Takeda, Protagonist drug for rare blood disorder

The FDA approved rusfertide, a new drug from Takeda and Protagonist Therapeutics to treat a rare blood disease. Rusfertide, which will be branded as Mimrylo, can now be prescribed for polycythemia vera, a disease in ...